Remicade®
Infliximab is a chimeric anti-TNF-α monoclonal antibody administered by IV infusion. Pioneering biologic for inflammatory conditions with extensive biosimilar market.
| Dosage Form | IV Injectable (Lyophilized Powder for Reconstitution) |
| Strength | 100 mg/vial |
| Storage | Store at 2–8°C. Do not freeze. Reconstituted solution for immediate use. |
| Category | Immunology |
| Availability | Available for Transfer |
Crohn's disease; ulcerative colitis; rheumatoid arthritis (with methotrexate); ankylosing spondylitis; psoriatic arthritis; plaque psoriasis.
Chimeric IgG1 monoclonal antibody that binds to soluble and transmembrane TNF-α, neutralizing its biological activity and inducing apoptosis of TNF-producing cells.
Each Burrard Pharmaceuticals technology transfer package for Infliximab includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier templates — available through Burrard Intelligence subscription.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Our team can deliver the complete know-how package within 2–21 business days. Book a consultation to discuss your specific requirements.